doi: 10.3389/fphar.2025.1562896 Received 23 January 2025 Accepted 05 May 2025 Published 02 June 2025 Corrected 09 June 2025 Volume 16 - 2025 Edited by Ahmed Ghallab, Leibniz Research Centre for Working Environment and Human Factors (IfADo), Germany Reviewed by Madlen Matz-Soja, Leipzig University, Germany Mohamed Albadry, University Hospital Jena, Germany Updates Copyright 2025 Sun, Shang, Lv, Liu, Wu and Geng
Such data patterns suggest that healthcare providers and patients are becoming more aware of Semaglutide's benefits in managing conditions such as Obesity And Type 2 Diabetes
Recommendations from the study include that more extensive multicenter studies or prospective clinical trials are needed to confirm findings and explore causality
Price depends on your dose, plan length, payment timing, and the compounding pharmacy and formulation